MoldCo, a Boston, MA-based company developing evidence-based solutions designed to restore metabolic health, clear harmful microbes, and reduce inflammation, raised $3M in Pre-Seed funding.
Backers included Starship Ventures, SALT, Conscience VC, Boost VC, Night Ventures, Bleu Capital, Behind Genius Ventures and Moth Fund.
The company intends to use the funds to to expand nationwide in 2025.
Led by CEO Ariana Thacker, MoldCo enables individuals to reclaim their health from mold. The company aims to provide accessible and evidence-based care, treatments and lab testing for mold toxicity, digitally. MoldCo’s approach is guided by a patented, published and evidence-based approach that has been used to treat over 30,000 patients with Mold Illness, also known as Chronic Inflammatory Response Syndrome (CIRS). Its customers receive access to mold-certified clinician care, specialized lab tests, and evidence-based treatments.
MoldCo is now accepting patients in select states.
FinSMEs
10/12/2024